Abstract: Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

Abstract: Disclosed is an improved approach to implement high availability for file servers in a virtualized computing environment. A high availability solution is provided that creates a global file system namespace across two clusters located at separate sites, where a synchronous storage replication is used to support the stretched container, allowing VMs and files stored in the container to be replicated in real-time between the two clusters.

Abstract: Examples of systems described herein may allow users to change from an application level disaster recovery system (e.g., an application level replication policy) to a share level disaster recovery system (e.g., a share level replication policy). The change may be made such that a base snapshot need not again be taken when beginning operation under the share level replication policy—rather, the base snapshot previously taken during application level replication may be used in some examples. That base snapshot may be leveraged, an initial set of common share snapshots established, and protection maintained going forward on a share level basis.

Abstract: Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

Abstract: Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that may cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders characterized or mediated by aberrant protein activity.

Abstract: A nanogrid system for managing power within a premises comprises a plurality of nanogrid nodes. Each nanogrid node includes a connection to a power source within the premises, a microgrid interconnection device (MID) configured to selectively disconnect from the power source, at least one power management component configured to provide backup power to one or more loads within a portion of the nanogrid system, and a peer-to-peer wireless connection with at least another nanogrid node of the plurality of nanogrid nodes. Each nanogrid node is configured to modify the operation of its MID and power management component based on information exchanged via the peer-to-peer wireless connection.

Abstract: A self-contained nanogrid system comprises a power supply input to couple to an external primary power source within a premises, a switch coupled to connect or disconnect the system from the primary power, and a battery as backup to the primary power source. The system further comprises a DC power bus coupled to the battery, an AC power bus coupled to the power supply input via the switch, and a bidirectional inverter coupled between the AC and DC power buses. The system further comprises an integrated load coupled to receive power from the AC power bus or the DC power bus, a power output to provide power from the AC power bus or the DC power bus to an external load, and a processing unit configured to control operations of the self-contained nanogrid system, including the switch.

Abstract: Methods, systems, and kits for generating placenta-like organoids in suspension or placenta-on-a-chip systems are described herein, as well as methods of use thereof. A placental organoid composition has a plurality of trophoblast cells derived from naïve-like stem cells in suspension cultures. The placental organoid composition can be prepared by seeding a single-cell suspension onto a culture surface in a first medium, centrifuging and incubating the single-cell suspension to form aggregates. A portion of the first media is replaced with a differentiation media and the aggregates are incubated for a period of time during which the aggregates differentiate into placental organoids. The composition can be used to assess drug toxicity and drug screening.

Abstract: A configurable, wearable electronic device is shown and described. The configurable, wearable electronic device may be configured to be worn around a user's neck via a lanyard and a special longitudinal insert of the configurable having an attached tether, worn on a user's clothing via a conforming cradle assembly or worn on a user's wrist by removing one or more longitudinal inserts of the configurable, wearable electronic device and connecting a wrist strap having two longitudinal inserts that fit into a respective channel of the configurable, wearable electronic device.

Abstract: The present invention provides assay systems and methods for detection of copy number variation at one or more loci and polymorphism detection at one or more loci in a mixed sample from an individual.

Abstract: A configurable, wearable electronic device is shown and described. The configurable, wearable electronic device may be configured to be worn around a user's neck via a lanyard and a special longitudinal insert of the configurable having an attached tether, worn on a user's clothing via a conforming cradle assembly or worn on a user's wrist by removing one or more longitudinal inserts of the configurable, wearable electronic device and connecting a wrist strap having two longitudinal inserts that fit into a respective channel of the configurable, wearable electronic device.

Abstract: Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that may cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders characterized or mediated by aberrant protein activity.

Abstract: A device for an elevator system has a blocking arrangement and a measuring arrangement, wherein the blocking arrangement connects a counterweight and/or a car of the elevator system to a rail system of the elevator system, and wherein the measuring arrangement maps a force transferred from the counterweight and/or car into the rail system as a force value.

Abstract: Disclosed and described herein are systems, methods and device for providing simultaneous non-invasive arterial and venous oxygen saturation. An ultra-thin and self-adherable optical electronic tattoo measures blood absorbance changes from multiple locations. Another sensor may be included to provide self-calibration. Using algorithms, the signals from the blood from the artery and vein can be better separated and yield accurate blood oxygen assessments.

Abstract: The present invention provides processes for determining accurate risk probabilities for fetal aneuploidies. Specifically, the invention provides non-invasive evaluation of genomic variations through chromosome-selective sequencing and non-host fraction data analysis of maternal samples.

Abstract: Examples of systems described herein provide for share-level disaster recovery on, for example, virtualized file servers by enabling additional snapshots, including self-service recovery (SSR) snapshot migration in addition to replication snapshot migration to a disaster recovery location. In examples, a disaster recovery location may receive a replication of a share of a file system, the snapshot configured for recovery of the share at the disaster recovery location. The replication snapshot may include one or more additional snapshots, each taken since a time of a previous replication snapshot. At least one of the one or more additional snapshots may include an SSR snapshot, identifiable based at least on a tag associated with a process used to create the SSR snapshot at a primary location. The at least one additional snapshot may be extracted for use by another instance of the process at the disaster recovery location.

Abstract: Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

Abstract: Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

Abstract: Described are the bifunctional compounds, compositions and methods of treating a disease or disorder characterized by aberrant extracellular-signal-regulated kinase 5 (ERK5) activity.

Abstract: The present application provides bifunctional compounds that act as protein degradation inducing moieties for cyclin-dependent kinase 4 (CDK4), cyclin-dependent kinase 6 (CDK6) and Ikaros Family Zinc Finger 2 (IKZF2), also known as Helios. Also disclosed are methods for the treatment of disorders modulated by CDK4, CDK6, and IKZF2.